FRIDAY 16 March 2012

PROGRAM
EORTC HEAD & NECK CANCER GROUP MEETING
FRIDAY 16 MARCH TO SATURDAY 17 MARCH 2012
INSTITUT JULES BORDET
121 BOULEVARD DE WATERLOO, 1000 BRUSSELS
FRIDAY 16 March 2012
13.00-14.00hrs
LUNCH
14.00-14.05hrs
Welcome and short introduction
14.05-15.00hrs
PRIMARY SETTING
14.05-14.30hrs
Update study proposal
Hans Langendijk
Jan Vermorken
A randomized phase II study: Standard cisplatinbased chemoradiation versus concomitant use of
EGFR-inhibitor/taxane/RT versus TPF induction
chemotherapy followed by concomitant use of
EGFR-inhibitor/taxane/RT in locally advanced HPVnegative patients.
14.30-15.00hrs
Discussion
15.00-15.30hrs
New study proposal
Hans Langendijk
A phase II study on individualized treatment in
elderly patients with squamous cell head and neck
cancer.
15.30-16.00hrs
Discussion
16.00-17.00hrs
TRANSLATIONAL RESEARCH
16.00-16.30hrs
EORTC protocol 90111-24111: Neoadjuvant BIBW
2992 followed by surgery in squamous cell
carcinoma of the head and neck: an EORTC NOCIHNCG window study.
16.30-16.50hrs
Discussion
17.00-19.00hrs
STEERING COMMITTEE MEETING (CLOSED)
19.30hrs
GROUP DINNER:
Jean-Pascal Machiels
SATURDAY 17 March 2012
8.30- 9.00hrs
WELCOME & COFFEE (Foyer ROOM A)
9.00-10.00hrs
HPV-POSITIVE OROPHRAYNGEAL CANCER
9.00- 9.30hrs
Status on the phase III study of the role of cetuximab
in low risk HPV related oropharyngeal carcinoma
(DE-ESCALATE study).
Hisham Mehanna
9.30- 9.45hrs
Testing a new statistical approach in connection to
the DE-ESCALATE study.
Sjoukje Oosting
9.45-10.00hrs
Discussion
10.00-11.00hrs
HIGH RISK POSTOPERATIVE SETTING
10.00-10.20hrs
Update study proposal
EORTC proposal for postoperative strategies in high
risk patients
10.20-10.40hrs
Hans Langendijk (on behalf
of Wilfried Budach)
Naomi Kiyota
Update study proposal
JCOG 1008: Phase II/III trial of Postoperative
Chemoradiotherapy comparing 3-Weekly Cisplatin
with Weekly Cisplatin in High Risk Patients with
Squamous cell carcinoma of Head and Neck
10.40-11.00hrs
Discussion
11.00-11.30hrs
COFFEE BREAK
11.30-12.00hrs
RARE TUMOURS
12.00-12.10hrs
The NCI- NCRN UK-EORTC platform on rare
tumors: focus on salivary gland tumors.
Ravi Karra
12.10-12.20hrs
A phase I/II study of HPV therapeutic vaccine
combined with anti-PD1 antibody for patients with
HPV-associated SCCHN
Amanda Psyrri
12.20-12.30hrs
Modulation of lymphocyte regulation in SCCHN: A
Amanda Psyrri
phase II study of antitumor activity of biweekly MDX1106 (Anti-PD-1, BMS-936558/ONO-4538) in
patients with recurrent/metastatic SCCHN
12.30-13.30hrs
BUSINESS MEETING
12.30-12.40hrs
Report
from
Subcommittee
12.40-12.50hrs
Report from the Quality of life Subcommittee
Elections
Other Business
13.30hrs
ADJOURN
the
Translational
Research Amanda Psyrri
Susanne Singer